
Pfizer's strong Q3 and raised 2026 EPS guidance ease patent expiration fears, keeping it a Buy for investors.
Pfizer Inc. delivered strong Q3 results driven by its oncology portfolio, Eliquis, and tafamidis franchise, with Eliquis revenue growing 25.2% year-over-year to about $2.5 billion. Despite concerns about an upcoming patent expiration cycle lasting ar...





